Filtered By:
Drug: Clopidogrel
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 1913 results found since Jan 2013.
Ischemic Stroke Management: Posthospitalization and Transition of Care
Am Fam Physician. 2023 Jul;108(1):70-77.ABSTRACTIschemic stroke is a major cause of morbidity and mortality worldwide. Ischemic stroke and transient ischemic attack exist on a continuum of the same disease process. Ischemic stroke is common, and more than 85% of stroke risk is attributed to modifiable risk factors. The initial management of acute stroke is usually performed in the emergency department and hospital settings. Family physicians have a key role in follow-up, ensuring that a complete diagnostic evaluation has been performed, addressing modifiable risk factors, facilitating rehabilitation, and managing chronic s...
Source: American Family Physician - July 13, 2023 Category: Primary Care Authors: Scott T Larson Brigit E Ray Jason Wilbur Source Type: research
Dual Versus Mono Antiplatelet Therapy in Patients with Acute Mild-to-Moderate Stroke: A Multicentre Perspective Cohort Study
ConclusionAspirin plus clopidogrel was associated with a reduction in the incidence of disability attributed to index stroke. There was no statistically significant difference in the incidence of moderate to severe bleeding complications between the two antiplatelet drug regimens.Trial Registration NumberChiCTR1900025214.
Source: Cardiovascular Drugs and Therapy - June 13, 2023 Category: Cardiology Source Type: research
CYP2C19 Loss-of-Function Variants Associated with Long-term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population
This study aims to determine whether CYP2C19 loss-of-function (LoF) variants were associated with long-term ischemic stroke risk in Chinese primary care patients treated with clopidogrel. Patients treated with clopidogrel were ascertained from a Chinese Electronic Medical Record linked with biobank for a retrospective cohort study. Their medical information was examined for the period from January 2018 to December 2021. Two CYP2C19 major loss of function variants (*2:rs4244285, *3: rs4986893) were genotyped. The clinical outcome was ischemic stroke event. Cox regression analysis was used to evaluate the association between...
Source: Clinical Pharmacology and Therapeutics - August 22, 2023 Category: Drugs & Pharmacology Authors: Peng Wu Ziqing Liu Zijian Tian Benrui Wu Jian Shao Qian Li Zhaoxu Geng Ying Pan Ke Lu Qiang Wang Tao Xu Kaixin Zhou Source Type: research
Clinical Updates on Antiplatelet Therapy for Secondary Prevention in Acute Ischemic Stroke
Acta Neurol Taiwan. 2023 Sep 30;32(3):138-144.ABSTRACTAntiplatelet therapy is the first-line management for noncardioembolic transient ischemic attack (TIA) and acute ischemic stroke (IS). Herein, we review the safety and efficacy of antiplatelet therapies in patients with IS and TIA, primarily focusing on the acute stage. We discuss current antiplatelet monotherapy and the factors influencing efficacy and continuation rate according to clinical trial data. Aspirin remains the most commonly used first-line antiplatelet agent for preventing noncardioembolic stroke recurrence, and clopidogrel, cilostazol, and ticagrelor are ...
Source: Acta Neurologica Taiwanica - September 7, 2023 Category: Neurology Authors: Tsung-Lin Lee Yu-Ming Chang Pi-Shan Sung Source Type: research
